Since 2020, Velocity Clinical Research has supported trials that contributed to 61 FDA-approved products — and we couldn’t be more proud of what that represents.
Those 61 FDA-approved products span an extraordinary range of therapeutic areas: cardiovascular disease, obesity and diabetes, Alzheimer’s disease, respiratory conditions including RSV and COVID-19, dermatology, liver disease, migraine, multiple sclerosis, alopecia areata, vaccines, and more. They include household names like Mounjaro, Zepbound, Wegovy, Kisunla, Rezdiffra, and Comirnaty — and countless others that are quietly changing lives for patients with rare and serious conditions.
This kind of breadth is the direct result of what happens when sites, technology, and talent operate as one unified organization. Across 70+ sites and 4 countries, with 200+ investigators and a central infrastructure built for speed, quality, and consistency, Velocity is purpose-built to support the kind of complex, high-volume trial portfolios that move science forward. Our 7x faster feasibility turnaround, integrated recruitment capabilities, and track record of meeting and exceeding enrollment goals give sponsors and CROs the confidence to bring us their most important programs.
To the sponsors and CROs who have trusted Velocity to deliver — thank you. Your confidence in our teams drives us to keep raising the bar.
To our staff across every site — the coordinators, investigators, nurses, regulatory specialists, and everyone in between — this milestone belongs to you. Your commitment to data quality and to every patient who walks through our doors is what makes results like these possible.
And to our patients — thank you. Every person who volunteers their time and health to participate in a clinical trial is helping write the next chapter of medicine. We are honored to be part of that journey with you.
Here’s to the next 61.
